Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenvatinib in HCC after Atezolizumab/Bevacizumab
NCT06138769Phase 2Active, not recruiting
- Sponsor
- Asan Medical Center
- Start
- Jul 2023
- Primary completion
- Nov 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of lenvatinib in hepatocellular carcinoma (HCC), sponsored by Asan Medical Center. Started Jul 2023; status: active, not recruiting.
02
Drugs
lenvatinib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT06138769.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06138769.